Drug intelligence / Profile preview

PB 103

Development stage: Phase 2
Lead developer: Precision Biotech Taiwan
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

PB 103 is a recombinant protein therapeutic candidate developed by PB Immune Therapeutics for the treatment and prevention of anti-drug antibodies (ADA). ADA formation is a significant clinical challenge where the patient's immune system recognizes a biologic drug as foreign, potentially neutralizing its therapeutic effect or causing adverse reactions. PB 103 is designed to induce antigen-specific immune tolerance, thereby suppressing the immune response against therapeutic proteins. The program is currently in Phase 1 clinical development, with a projected development timeline extending through 2027.

Other names: allogeneic NK cells PB103allogeneic natural killer (NK) cells PB103

Beyond the preview

Go deeper on PB 103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PB 103.

Explore the full profile